Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Androsta-4,9(11)-diene-3,17-dione is a synthetic steroidal compound investigated for its multi-target anti-cancer properties in estrogen receptor-positive (ER+) breast cancer. It acts as a polypharmacological agent, functioning as an aromatase inhibitor, an androgen receptor (AR) agonist, and a modulator of estrogen receptor (ER) signaling. In preclinical studies using MCF-7aro and AI-resistant LTEDaro cell lines, the compound has demonstrated the ability to arrest cell cycle progression and induce apoptosis, potentially overcoming resistance to standard endocrine therapies like aromatase inhibitors and anti-estrogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on androsta-4,9(11)-diene-3,17-dione.